Key Takeaways
- Cenexi drag masks base-business strength: A one-month European holiday shutdown left Cenexi EBITDA-negative for the quarter, but the base business ex-Cenexi delivered a 34% EBITDA margin, up from 28% YoY.
- US pricing has stabilised: Management confirmed the sequential price erosion that characterised prior quarters "has stopped" and the environment is "stable," allowing volume-led growth from older products.
- Enoxaparin’s return is a margin headwind: The product begins shipping in larger volumes next quarter, and because it carries lower margins, management is guiding base-business EBITDA down to a 30%–32% target range.
- Cenexi integration is now an execution story: A €60 mn capex programme, 25 tech-transfer projects, and a phase-out of low-margin legacy business are underway, but commercialisation of new volumes is not expected until end-FY25 or later.
- What to watch next quarter: Whether Cenexi revenue rebounds to the promised ~€50–55 mn run-rate, the pace of Enoxaparin’s margin dilution, and any update on the buyback evaluation.
Cenexi Acquisition: The Quarter’s Distortion
- Shutdown mechanics: French and Belgian operations close for 3–4 weeks every August for an industry-wide holiday. Cenexi booked only two months of revenue while incurring a full quarter of fixed costs, pushing it to an EBITDA loss.
- Normalised run-rate: A full quarter should deliver €50–55 mn of revenue and 10%–11% EBITDA margins; the Q2 loss is consistent with management’s internal estimates and is expected to reverse as revenue normalises.
- Gross margin contribution was healthy: Despite the operating loss, Cenexi’s gross contribution margin improved to 77%, up from the prior quarter.
- Next-quarter rebound expected: Management stated Q3 revenue from Cenexi should be roughly 50% higher to cover the EBITDA gap, implying a return to near-normal operations.
- Consolidation inflated working capital: Consolidated inventory rose to ~₹2,000 crore and debtors increased, both driven by Cenexi consolidation; standalone inventory actually fell from ₹1,900 crore to ₹1,700 crore.
Srinivas Sadu: "I think we can't comment, it is too early, maybe at the end of next year we will be better off, so currently we want to stick to that number."
Base Business Margins: Strong Today, Softer Tomorrow
- Ex-Cenexi EBITDA jumped to 34%: The base business delivered a 600 bps YoY margin improvement, helped by a 5% reduction in power costs and flat manpower expenses, alongside improved US margins.
- Gross margin widened sharply: Consolidated gross margin reached 62% versus 50% in Q2 FY23, reflecting both the high gross margin profile of Cenexi and underlying improvement in the base business.
- Enoxaparin’s return resets the target lower: The product will begin shipping in larger volumes from Q3 and Q4. Because Enoxaparin carries lower margins than the portfolio average, management explicitly guided base-business EBITDA down to a 30%–32% range.
- Volume-over-price strategy is deliberate: With new production lines coming on track, the company can absorb more fixed costs and is being "a little aggressive on pricing" on products like Ketorolac and Rocuronium to drive volume uptake while maintaining margins.
Srinivas Sadu: "I still consider 30%–32% could be the targeted EBITDA margin because Enoxa, compared to low-margin products, will start to gain from the next quarter and subsequent quarters."
US Market: Stability Returns
- Sequential growth resumed: US sales rose 22% QoQ and 9% YoY, driven by volume increases in older products including Ketorolac, Rocuronium, Fluorouracil, and Esmolol.
- Price erosion has stopped: Management stated that the quarterly price falls seen in prior periods are no longer occurring; the pricing environment is now "stable." Competitive intensity remains from B2C players, but some competitors have withdrawn due to regulatory issues or lack of margins.
- Niche launches gaining traction: Newly launched products Calcitriol, Fluphenazine, and Desmopressin are seeing partner uptake, and regadenoson is performing well with no price erosion.
- Rel launches tied to Athenex bankruptcy: Products acquired from the Athenex estate began shipping after the acquiring company liquidated old inventory, creating a ~2-month lag. Relaunch inventory is typically kept lean.
- Base-business growth outlook is qualitative only: Management expects steady sequential improvement from the ~₹1,000 crore US base but declined to quantify it, citing an inability to "lock the specific number."
Srinivas Sadu: "I would say the drop has stopped; earlier, every quarter, you used to see a fall in prices. At least that is not happening now. So, it is basically a little stable."
Cenexi Turnaround: Capex, Tech Transfer, and a Long Fuse
- €60 mn investment programme underway: Approximately €30–35 mn of this is capex, directed at high-speed ampoule lines and high-end pre-filled syringe (PFS) lines; the spend was anticipated during acquisition evaluation and will deploy over the next 18 months.
- 25 tech-transfer projects in flight: These projects, moving from Gland’s pipeline into Cenexi, are expected to generate commercial volumes only at the end of next year or beginning of 2025, creating a multi-quarter lag before new revenue materialises.
- Low-margin legacy business being phased out: Some existing Cenexi business will be deliberately shed to make room for higher-value newly secured contracts, meaning revenue growth will be modest until tech-transfer batches ship commercially.
- Medium-term margin target is 13%–15% EBITDA: Management is currently analysing whether margins can move above this range but stated it is too early to commit to anything higher; OTIF (on-time in-full) improvement is a key operational focus.
- Next-year shutdown is structural, not a surprise: The August closure is an annual French and Belgian industry practice and will recur; management is evaluating optimum inventory levels to avoid dispatch disruption next year but has no plan yet.
Rest of World and Other Markets: Patchy, with a China Option
- ROW revenue contracted 9% QoQ: The decline was driven by Europe, where the business is concentrated in Enoxaparin, Heparin, and Caspofungin; management attributed the drop to shipment timing and Enoxaparin pricing pressure rather than structural demand destruction.
- Volume and demand have softened: Competition is high in other markets, pricing is at very low margins, and overall demand has declined. The largest ROW market is expected to recover partially from next quarter.
- Cenexi opens a new ROW channel: Cenexi’s partners have their own ROW sales networks and may take Gland products into those markets; with a lower base, ROW should grow faster than the US and Europe.
- India grew 21% YoY: The domestic market delivered strong performance in the quarter.
- China: one product launched, one more coming: The launched product is selling only in the private sector; management hopes it enters the VPB tender next year for a volume step-up. A second product is expected to launch next quarter.
Srinivas Sadu: "It is more of the timing which quarter it goes than anything else and of course the pricing of Enoxa."
Capital Allocation and Pipeline
- Buyback under evaluation: Return on net worth is approximately 10%, and management confirmed a buyback is "currently under evaluation" but offered no further detail.
- Complex pipeline advancing: At least three complex products will be ready for submission in the next 5–6 months, with approvals expected next year or later.
- Plasma project progressing: Batches are currently under manufacturing.
- Capex guidance provided: Base-business capex is pegged at ₹250–300 crore for FY24 and around ₹300 crore for FY25, separate from the Cenexi €30–35 mn programme.
- Revenue guidance remains withheld: Management explicitly declined to reinstate revenue guidance, offering only a qualitative commitment to "steady growth quarter-on-quarter."
Srinivas Sadu: "We are still staying away from giving the guidance, but the idea is to give steady growth quarter-on-quarter. That is how we are seeing the next few quarters."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Cenexi quarterly revenue run-rate | €50–55 mn per full quarter | From Q3 FY24 onwards |
| Cenexi annual EBITDA margin | 10%–11% | FY24, normalising after shutdown |
| Base business ex-Cenexi EBITDA margin | 30%–32% | From Q3 FY24, as Enoxaparin volumes return |
| Cenexi medium-term EBITDA margin | 13%–15% | Medium-term; too early to commit to higher |
| Cenexi capex programme | €30–35 mn (of €60 mn total investment) | Over next 18 months |
| Cenexi tech-transfer commercialisation | Volumes from ~25 projects begin | End of next year / beginning of 2025 |
| Base business capex FY24 | ₹250–300 crore | FY24 |
| Base business capex FY25 | ~₹300 crore | FY25 |
| Complex product submissions | At least 3 products ready for filing | Next 5–6 months |
| China second product launch | One more product launched | Next quarter |
| US base business growth | Steady sequential improvement from ~₹1,000 crore base | Next few quarters |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹1,373.4 cr, +32% YoY and +14% QoQ |
| Gross margin | 62%, up from 50% in Q2 FY23 |
| EBITDA | ₹320.5 cr, +8% YoY |
| EBITDA margin | 23%, vs 28% in Q2 FY23 |
| Base business (Ex-Cenexi) EBITDA margin | 34%, up from 28% in Q2 FY23 |
| Net profit | ₹194.1 cr, -20% YoY |
| PAT margin | 14% |
| US market revenue growth | +22% QoQ, +9% YoY |
| Core markets revenue share | 74% of revenue, up from 72% in Q2 FY23 |
| India market revenue growth | +21% YoY |
| Rest of world markets revenue share | 19% of revenue, -9% QoQ |
| R&D expense | ₹35.1 cr, 3% of operating revenue (3.5% Ex-Cenexi) |
| ANDAs filed in the quarter | 1 filed, 5 approved |
| Cenexi revenue | ₹358.8 cr for two months of operations |
| Cenexi EBITDA | negative ₹26.8 cr |
| Cash and equivalents (group) | ₹2,262.7 cr, net cash position ₹1,950 cr |
| Average cash conversion cycle | 196 days, improved from 226 days in H1 FY23 |